BRAIN TUMOR LIBRARY
Glioblastoma | Prognosis
48



Home > Brain tumor library > Glioblastoma > Prognosis



Literature sections:
Overviews
Newly diagnosed and recurrent tumors
Newly diagnosed tumors
Recurrent tumors
- Pattern of recurrence
- Relapse prediction
- Radiotherapy
- Surgery

Tumor variants:
Gliosarcoma



Overviews




Houdova Megova M, Drábek J, Dwight Z, Trojanec R, Koudeláková V, Vrbková J, Kalita O, Mlcochova S, Rabcanova M, Hajdúch M.
Isocitrate Dehydrogenase Mutations are Better Prognostic Marker than O6-methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastomas - a Retrospective, Single-centre Molecular Genetics Study of Gliomas.
Klin Onkol. 2017 Fall;30(5):361-371. doi: 10.14735/amko2017361. Accepted: 23. 7. 2017.
Source | Abstract | Full text | Similar articles



SURVIVAL



deSouza RM, Shaweis H, Han C, Sivasubramiam V, Brazil L, Beaney R, Sadler G, Al-Sarraj S, Hampton T, Logan J, Hurwitz V, Bhangoo R, Gullan R, Ashkan K.
Has the survival of patients with glioblastoma changed over the years?
Br J Cancer. 2016 Jan 19;114(2):146-50. doi: 10.1038/bjc.2015.421. Epub 2015 Dec 15.
Source | Abstract | Full text | Similar articles




Gately L, McLachlan SA, Philip J, Ruben J, Dowling A.
Long-term survivors of glioblastoma: a closer look.
J Neurooncol. 2017 Oct 27. doi: 10.1007/s11060-017-2635-1. [Epub ahead of print]
Source | Abstract | Full text | Similar articles




Gately L, McLachlan SA, Dowling A, Philip J.
Life beyond a diagnosis of glioblastoma: a systematic review of the literature.
J Cancer Surviv. 2017 Aug;11(4):447-452. doi: 10.1007/s11764-017-0602-7. Epub 2017 Feb 13.
Source | Abstract | Full text | Similar articles




Gramatzki D, Kickingereder P, Hentschel B, Felsberg J, Herrlinger U, Schackert G, Tonn JC, Westphal M, Sabel M, Schlegel U, Wick W, Pietsch T, Reifenberger G, Loeffler M, Bendszus M, Weller M.
Limited role for extended maintenance temozolomide for newly diagnosed glioblastoma.
Neurology. 2017 Mar 15. pii: 10.1212/WNL.0000000000003809. doi: 10.1212/WNL.0000000000003809. [Epub ahead of print]

Source | Abstract | Full text | Similar articles




Klement RJ, Champ CE.
Corticosteroids compromise survival in glioblastoma in part through their elevation of blood glucose levels.
Brain. 2016 Dec 21. pii: aww324. doi: 10.1093/brain/aww324. [Epub ahead of print]
Source | Abstract | Full text | Similar articles




Johnson DR, Omuro AMP, Ravelo A, Sommer N, Guerin A, Ionescu-Ittu R, Shi S, Macalalad A, Uhm JH.
Overall survival in patients with glioblastoma before and after bevacizumab approval.
Curr Med Res Opin. 2017 Oct 13:1-18. doi: 10.1080/03007995.2017.1392294. [Epub ahead of print]
Source | Abstract | Full text | Similar articles




Morgan ER, Norman A, Laing K, Seal MD.
Treatment and outcomes for glioblastoma in elderly compared with non-elderly patients: a population-based study.
Curr Oncol. 2017 Apr;24(2):e92-e98. doi: 10.3747/co.24.3424. Epub 2017 Apr 27.
Source | Abstract | Full text | Similar articles




Pitter KL, Tamagno I, Alikhanyan K, Hosni-Ahmed A, Pattwell SS, Donnola S, Dai C, Ozawa T, Chang M, Chan TA, Beal K, Bishop AJ, Barker CA, Jones TS, Hentschel B, Gorlia T, Schlegel U, Stupp R, Weller M, Holland EC, Hambardzumyan D.
Corticosteroids compromise survival in glioblastoma.
Brain. 2016 May;139(Pt 5):1458-71. doi: 10.1093/brain/aww046. Epub 2016 Mar 28.
Source | Abstract | Full text | Similar articles




Wang PF, Song HW, Cai HQ, Kong LW, Yao K, Jiang T, Li SW, Yan CX.
Preoperative inflammation markers and IDH mutation status predict glioblastoma patient survival.
Oncotarget. 2017 Feb 9. doi: 10.18632/oncotarget.15235. [Epub ahead of print]
Source | Abstract | Full text | Similar articles




Weller M, Holland EC, Hambardzumyan D.
Reply: Corticosteroids compromise survival in glioblastoma in part through their elevation of blood glucose levels.
Brain. 2016 Dec 21. pii: aww325. doi: 10.1093/brain/aww325. [Epub ahead of print]
Source | Abstract | Full text | Similar articles



PEDIATRIC PATIENTS



Lam S, Lin Y, Zinn P, Su J, Pan IW.
Patient and treatment factors associated with survival among pediatric glioblastoma patients: A Surveillance, Epidemiology, and End Results study.
J Clin Neurosci. 2017 Oct 25. pii: S0967-5868(17)31102-5. doi: 10.1016/j.jocn.2017.10.041. [Epub ahead of print]
Source | Abstract | Full text | Similar articles



EPILEPTIC FEATURES AND SURVIVAL



Toledo M, Sarria-Estrada S, Quintana M, Maldonado X, Martinez-Ricarte F, Rodon J, Auger C, Aizpurua M, Salas-Puig J, Santamarina E, Martinez-Saez E.
Epileptic features and survival in glioblastomas presenting with seizures.
Epilepsy Res. 2016 Dec 26;130:1-6. doi: 10.1016/j.eplepsyres.2016.12.013. [Epub ahead of print]
Source | Abstract | Full text | Similar articles



Newly diagnosed or recurrent tumors



ELDERLY PATIENTS



Rigamonti A, Imbesi F, Silvani A, Grimod G, Prone V, Gaviani P, Ardizzoia A, Milanesi I, Arienti V, Agostoni E, Di Meco F, Salmaggi A.
Pattern of care and outcome in elderly patients with glioblastoma: Data in 151 patients from 3 Lombardia Hospitals.
J Neurol Sci. 2017 Jul 15;378:3-8. doi: 10.1016/j.jns.2017.04.030. Epub 2017 Apr 18.
Source | Abstract | Full text | Similar articles



ANGIOGENESIS INHIBITORS



Baumgarten P, Blank AE, Franz K, Hattingen E, Dunst M, Zeiner P, Hoffmann K, Bähr O, Mäder L, Goeppert B, Machein M, Seifert V, Steinbach JP, Plate KH, Harter PN, Mittelbronn M.
Differential expression of vascular endothelial growth factor A, its receptors VEGFR-1, -2, and -3 and co-receptors neuropilin-1 and -2 does not predict bevacizumab response in human astrocytomas.
Neuro Oncol. 2016 Feb;18(2):173-83. doi: 10.1093/neuonc/nov288. Epub 2015 Nov 30.
Source | Abstract | Full text | Similar articles




Kessler T.
Predicting glioblastoma response to bevacizumab through marker profiling?
Neuro Oncol. 2016 Feb;18(2):149-50. doi: 10.1093/neuonc/nov320.
Source | Abstract | Full text | Similar articles



BEVACIZUMAB



Mamo A, Baig A, Azam M, Rho YS, Sahebjam S, Muanza T, Owen S, Petrecca K, Guiot MC, Al-Shami J, Sharma R, Kavan P.
Progression pattern and adverse events with bevacizumab in glioblastoma.
Curr Oncol. 2016 Oct;23(5):e468-e471. Epub 2016 Oct 25.
Source | Abstract | Full text | Similar articles



CORTICOSTEROIDS



Alkhalili K, Zenonos G, Fernandez-Miranda JC.
Do Corticosteroids Compromise Survival in Glioblastoma?
Neurosurgery. 2016 Oct;79(4):N15-6. doi: 10.1227/01.neu.0000499707.66337.09.
Source | Abstract | Full text | Similar articles




Pitter KL, Tamagno I, Alikhanyan K, Hosni-Ahmed A, Pattwell SS, Donnola S, Dai C, Ozawa T, Chang M, Chan TA, Beal K, Bishop AJ, Barker CA, Jones TS, Hentschel B, Gorlia T, Schlegel U, Stupp R, Weller M, Holland EC, Hambardzumyan D.
Corticosteroids compromise survival in glioblastoma.
Brain. 2016 May;139(Pt 5):1458-71. doi: 10.1093/brain/aww046. Epub 2016 Mar 28.
Source | Abstract | Full text | Similar articles



IDH 1 EXPRESSION / MUTATION



Khan I, Waqas M, Shamim MS.
Prognostic significance of IDH 1 mutation in patients with glioblastoma multiforme.
J Pak Med Assoc. 2017 May;67(5):816-817.
Source | Abstract | Full text | Similar articles




Zhai L, Ladomersky E, Lauing KL, Wu M, Genet M, Gritsina G, Győrffy B, Brastianos PK, Binder D, Sosman JA, Giles FJ, James CD, Horbinski C, Stupp R, Wainwright DA.
Infiltrating T cells increase IDO1 expression in glioblastoma and contribute to decreased patient survival.
Clin Cancer Res. 2017 Jul 27. pii: clincanres.0120.2017. doi: 10.1158/1078-0432.CCR-17-0120. [Epub ahead of print]
Source | Abstract | Full text | Similar articles



IMAGING



Chaddad A, Desrosiers C, Toews M.
Radiomic analysis of multi-contrast brain MRI for the prediction of survival in patients with glioblastoma multiforme.
Conf Proc IEEE Eng Med Biol Soc. 2016 Aug;2016:4035-4038. doi: 10.1109/EMBC.2016.7591612.
Source | Abstract | Full text | Similar articles




Henker C, Kriesen T, Glass Ä, Schneider B, Piek J.
Volumetric quantification of glioblastoma: experiences with different measurement techniques and impact on survival.
J Neurooncol. 2017 Jul 28. doi: 10.1007/s11060-017-2587-5. [Epub ahead of print]
Source | Abstract | Full text | Similar articles



TIME-TO-PROGRESSION



Park JE, Ryu KH, Kim HS, Kim HW, Shim WH, Jung SC, Choi CG, Kim SJ, Kim JH.
Perfusion of surgical cavity wall enhancement in early post-treatment MR imaging may stratify the time-to-progression in glioblastoma.
PLoS One. 2017 Jul 21;12(7):e0181933. doi: 10.1371/journal.pone.0181933. eCollection 2017.
Source | Abstract | Full text | Similar articles



NEUTROPENIA



Saito T, Sugiyama K, Hama S, Yamasaki F, Takayasu T, Nosaka R, Muragaki Y, Kawamata T, Kurisu K.
Prognostic importance of temozolomide-induced neutropenia in glioblastoma, IDH-wildtype patients.
Neurosurg Rev. 2017 Sep 9. doi: 10.1007/s10143-017-0903-3. [Epub ahead of print]
Source | Abstract | Full text | Similar articles



RADIOTHERAPY



Foro Arnalot P, Pera O, Rodriguez N, Sanz X, Reig A, Membrive I, Ortiz A, Granados R, Algara M.
Influence of incidental radiation dose in the subventricular zone on survival in patients with glioblastoma multiforme treated with surgery, radiotherapy, and temozolomide.
Clin Transl Oncol. 2017 Apr 7. doi: 10.1007/s12094-017-1659-5. [Epub ahead of print]
Source | Abstract | Full text | Similar articles




Pinel B, Duchesne M, Godet J, Milin S, Berger A, Wager M, Karayan-Tapon L.
Mesenchymal subtype of glioblastomas with high DNA-PKcs expression is associated with better response to radiotherapy and temozolomide.
J Neurooncol. 2017 Jan 10. doi: 10.1007/s11060-016-2367-7. [Epub ahead of print]
Source | Abstract | Full text | Similar articles



RISK OF SUBSEQUENT CANCER



Li X, Li Y, Cao Y, Li P, Liang B, Sun J, Feng E.
Risk of subsequent cancer among pediatric, adult and elderly patients following a primary diagnosis of glioblastoma multiforme: a population-based study of the SEER database.
Int J Neurosci. 2017 Mar 17:1-7. doi: 10.1080/00207454.2017.1288624. [Epub ahead of print]

Source | Abstract | Full text | Similar articles



SURGERY



Behling F, Kaltenstadler M, Noell S, Schittenhelm J, Bender B, Eckert F, Tabatabai G, Tatagiba M, Skardelly M.
The prognostic impact of ventricular opening in glioblastoma surgery: a retrospective single center analysis.
World Neurosurg. 2017 Jul 17. pii: S1878-8750(17)31134-8. doi: 10.1016/j.wneu.2017.07.034. [Epub ahead of print]
Source | Abstract | Full text | Similar articles



SUBVENTRICULAR ZONE



Mistry AM, Dewan MC, White-Dzuro GA, Brinson PR, Weaver KD, Thompson RC, Ihrie RA, Chambless LB.
Decreased survival in glioblastomas is specific to contact with the ventricular-subventricular zone, not subgranular zone or corpus callosum.
J Neurooncol. 2017 Jan 10. doi: 10.1007/s11060-017-2374-3. [Epub ahead of print]
Source | Abstract | Full text | Similar articles



TUMORSPHERES


**

D'Alessandris QG, Biffoni M, Martini M, Runci D, Buccarelli M, Cenci T, Signore M, Stancato L, Olivi A, De Maria R, Larocca LM, Ricci-Vitiani L, Pallini R.
The clinical value of patient-derived glioblastoma tumorspheres in predicting treatment response.
Neuro Oncol. 2017 Feb 13. doi: 10.1093/neuonc/now304. [Epub ahead of print]
Source | Abstract | Full text | Similar articles



WALKING ABILITY



Liljehult MM, Buus L, Liljehult J, Rasmussen BK.
Walking ability in patients with glioblastoma: prognostic value of the Berg Balance Scale and the 10 meter walk test.
J Neurooncol. 2017 Jul 27. doi: 10.1007/s11060-017-2579-5. [Epub ahead of print]
Source | Abstract | Full text | Similar articles | Synopsis



Newly diagnosed tumors



NOMOGRAMS



Bredel M.
Nomograms as clinicobiological predictors of survival in glioblastoma.
Lancet Oncol. 2008 Jan;9(1):5-6. doi: 10.1016/S1470-2045(07)70390-X.
Source | Abstract | Full text | Similar articles




Gittleman H, Lim D, Kattan MW, Chakravarti A, Gilbert MR, Lassman AB, Lo SS, Machtay M, Sloan AE, Sulman EP, Tian D, Vogelbaum MA, Wang TJC, Penas-Prado M, Youssef E, Blumenthal DT, Zhang P, Mehta MP, Barnholtz-Sloan JS.
An independently validated nomogram for individualized estimation of survival among patients with newly diagnosed glioblastoma: NRG Oncology RTOG 0525 and 0825.
Neuro Oncol. 2017 May 1;19(5):669-677. doi: 10.1093/neuonc/now208. Epub 2016 Sep 23.
Source | Abstract | Full text | Similar articles




Gittleman H, Lim D, Kattan MW, Chakravarti A, Gilbert MR, Lassman AB, Lo SS, Machtay M, Sloan AE, Sulman EP, Tian D, Vogelbaum MA, Wang TJ, Penas-Prado M, Youssef E, Blumenthal DT, Zhang P, Mehta MP, Barnholtz-Sloan JS.
An independently validated nomogram for individualized estimation of survival among patients with newly diagnosed glioblastoma: NRG Oncology RTOG 0525 and 0825.
Neuro Oncol. 2016 Sep 23. pii: now208. [Epub ahead of print]
Source | Abstract | Full text | Similar articles




Gorlia T, van den Bent MJ, Hegi ME, Mirimanoff RO, Weller M, Cairncross JG, Eisenhauer E, Belanger K, Brandes AA, Allgeier A, Lacombe D, Stupp R.
Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3.
Lancet Oncol. 2008 Jan;9(1):29-38. Epub 2007 Dec 21.
Source | Abstract | Full text | Similar articles



ANGIOGENESIS INHIBITORS



Chinot OL, Nishikawa R, Mason W, Henriksson R, Saran F, Cloughesy T, Garcia J, Revil C, Abrey L, Wick W.
Upfront bevacizumab may extend survival for glioblastoma patients who do not receive second-line therapy: an exploratory analysis of AVAglio.
Neuro Oncol. 2016 Mar 22. pii: now046. [Epub ahead of print]
Source | Abstract | Full text | Similar articles




Malkki H.
Neuro-oncology: Bevacizumab prolongs progression-free survival but not overall survival in newly diagnosed glioblastoma.
Nat Rev Neurol. 2014 Apr;10(4):179. doi: 10.1038/nrneurol.2014.47. Epub 2014 Mar 18.
Source | Abstract | Full text | Similar articles




Wang Y, Xing D, Zhao M, Wang J, Yang Y.
The Role of a Single Angiogenesis Inhibitor in the Treatment of Recurrent Glioblastoma Multiforme: A Meta-Analysis and Systematic Review.
PLoS One. 2016 Mar 23;11(3):e0152170. doi: 10.1371/journal.pone.0152170. eCollection 2016.
Source | Abstract | Full text | Similar articles



CHEMORADIOTHERAPY


EXTENDED ADJUVANT TEMOZOLOMIDE



Blumenthal DT, Gorlia T, Gilbert MR, Kim MM, Burt Nabors L, Mason WP, Hegi ME, Zhang P, Golfinopoulos V, Perry JR, Hyun Nam D, Erridge SC, Corn BW, Mirimanoff RO, Brown PD, Baumert BG, Mehta MP, van den Bent MJ, Reardon DA, Weller M, Stupp R.
Is more better? The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma: a secondary analysis of EORTC and NRG Oncology/RTOG.
Neuro Oncol. 2017 Mar 24. doi: 10.1093/neuonc/nox025. [Epub ahead of print]
Source | Abstract | Full text | Similar articles



DELAYING CHEMORADIOTHERAPY AFTER SURGERY



Louvel G, Metellus P, Noel G, Peeters S, Guyotat J, Duntze J, Le Reste PJ, Dam Hieu P, Faillot T, Litre F, Desse N, Petit A, Emery E, Voirin J, Peltier J, Caire F, Vignes JR, Barat JL, Langlois O, Menei P, Dumont SN, Zanello M, Dezamis E, Dhermain F, Pallud J; Club de Neuro-Oncologie of Société Française deNeurochirurgie.
Delaying standard combined chemoradiotherapy after surgical resection does not impact survival in newly diagnosed glioblastoma patients.
Radiother Oncol. 2016 Jan;118(1):9-15. doi: 10.1016/j.radonc.2016.01.001. Epub 2016 Jan 11.
Source | Abstract | Full text | Similar articles




Osborn VW, Lee A, Garay E, Safdieh J, Schreiber D.
Impact of Timing of Adjuvant Chemoradiation for Glioblastoma in a Large Hospital Database.
Neurosurgery. 2017 Oct 28. doi: 10.1093/neuros/nyx497. [Epub ahead of print]
Source | Abstract | Full text | Similar articles



INFARCT VOLUME



Bette S, Wiestler B, Kaesmacher J, Huber T, Gerhardt J, Barz M, Delbridge C, Ryang YM, Ringel F, Zimmer C, Meyer B, Boeckh-Behrens T, Kirschke JS, Gempt J.
Infarct volume after glioblastoma surgery as an independent prognostic factor.
Oncotarget. 2016 Aug 22. doi: 10.18632/oncotarget.11482. [Epub ahead of print]
Source | Abstract | Full text | Similar articles



MRI IMAGING



Chang W, Pope WB, Harris RJ, Hardy AJ, Leu K, Mody RR, Nghiemphu PL, Lai A, Cloughesy TF, Ellingson BM.
Diffusion MR Characteristics Following Concurrent Radiochemotherapy Predicts Progression-Free and Overall Survival in Newly Diagnosed Glioblastoma.
Tomography. 2015 Sep;1(1):37-43.
Source | Abstract | Full text | Similar articles



p53 MUTATIONS



Shiraishi S, Tada K, Nakamura H, Makino K, Kochi M, Saya H, Kuratsu J, Ushio Y.
Influence of p53 mutations on prognosis of patients with glioblastoma
Cancer. 2002 Jul 11;95(2):249-57

Source | Abstract | Full text | Similar articles



PET IMAGING



Bosnyák E, Michelhaugh SK, Klinger NV, Kamson DO, Barger GR, Mittal S, Juhász C.
Prognostic Molecular and Imaging Biomarkers in Primary Glioblastoma.
Clin Nucl Med. 2017 May;42(5):341-347. doi: 10.1097/RLU.0000000000001577.
Source | Abstract | Full text | Similar articles



RADIOTHERAPY



Arvold ND, Cefalu M, Wang Y, Zigler C, Schrag D, Dominici F.
Comparative effectiveness of radiotherapy with vs. without temozolomide in older patients with glioblastoma.
J Neurooncol. 2016 Oct 21. [Epub ahead of print]
Source | Abstract | Full text | Similar articles



ELDERLY PATIENTS



Franceschi E, Depenni R, Paccapelo A, Ermani M, Faedi M, Sturiale C, Michiara M, Servadei F, Pavesi G, Urbini B, Pisanello A, Crisi G, Cavallo MA, Dazzi C, Biasini C, Bertolini F, Mucciarini C, Pasini G, Baruzzi A, Brandes AA; PERNO Study Group.
Which elderly newly diagnosed glioblastoma patients can benefit from radiotherapy and temozolomide? A PERNO prospective study.
J Neurooncol. 2016 May;128(1):157-162. doi: 10.1007/s11060-016-2093-1. Epub 2016 Mar 4.
Source | Abstract | Full text | Similar articles




Guedes de Castro D, Matiello J, Roa W, Ghosh S, Kepka L, Kumar N, Sinaika V, Lomidze D, Hentati D, Rosenblatt E, Fidarova E.
Survival Outcomes With Short-Course Radiation Therapy in Elderly Patients With Glioblastoma: Data From a Randomized Phase 3 Trial.
Int J Radiat Oncol Biol Phys. 2017 Jul 15;98(4):931-938. doi: 10.1016/j.ijrobp.2017.03.037. Epub 2017 Mar 30.
Source | Abstract | Full text | Similar articles




Harris G, Jayamanne D, Wheeler H, Gzell C, Kastelan M, Schembri G, Brazier D, Cook R, Parkinson J, Khasraw M, Louw S, Back M.
Survival Outcomes of Elderly Patients With Glioblastoma Multiforme in Their 75th Year or Older Treated With Adjuvant Therapy.
Int J Radiat Oncol Biol Phys. 2017 Jul 15;98(4):802-810. doi: 10.1016/j.ijrobp.2017.02.028. Epub 2017 Feb 21.
Source | Abstract | Full text | Similar articles




Lombardi G, Pace A, Pasqualetti F, Rizzato S, Faedi M, Anghileri E, Nicolotto E, Bazzoli E, Bellu L, Villani V, Fabi A, Ferrazza P, Gurrieri L, Dall'Agata M, Eoli M, Della Puppa A, Pambuku A, D'Avella D, Berti F, Rudà R, Zagonel V.
Predictors of survival and effect of short (40 Gy) or standard-course (60 Gy) irradiation plus concomitant temozolomide in elderly patients with glioblastoma: a multicenter retrospective study of AINO (Italian Association of Neuro-Oncology).
J Neurooncol. 2015 Nov;125(2):359-67. doi: 10.1007/s11060-015-1923-x. Epub 2015 Sep 30.
Source | Abstract | Full text | Similar articles




Minniti G, Scaringi C, Lanzetta G, Terrenato I, Esposito V, Arcella A, Pace A, Giangaspero F, Bozzao A, Enrici RM.
Standard (60 Gy) or short-course (40 Gy) irradiation plus concomitant and adjuvant temozolomide for elderly patients with glioblastoma: a propensity-matched analysis.
Int J Radiat Oncol Biol Phys. 2015 Jan 1;91(1):109-15. doi: 10.1016/j.ijrobp.2014.09.013. Epub 2014 Oct 25.
Source | Abstract | Full text | Similar articles




Minniti G, Scaringi C, Baldoni A, Lanzetta G, De Sanctis V, Esposito V, Enrici RM.
Health-related quality of life in elderly patients with newly diagnosed glioblastoma treated with short-course radiation therapy plus concomitant and adjuvant temozolomide.
Int J Radiat Oncol Biol Phys. 2013 Jun 1;86(2):285-91. doi: 10.1016/j.ijrobp.2013.02.013.
Source | Abstract | Full text | Similar articles




Minniti G, Lanzetta G, Scaringi C, Caporello P, Salvati M, Arcella A, De Sanctis V, Giangaspero F, Enrici RM.
Phase II study of short-course radiotherapy plus concomitant and adjuvant temozolomide in elderly patients with glioblastoma.
Int J Radiat Oncol Biol Phys. 2012 May 1;83(1):93-9. doi: 10.1016/j.ijrobp.2011.06.1992. Epub 2011 Nov 11.
Source | Abstract | Full text | Similar articles




Muni R, Minniti G, Lanzetta G, Caporello P, Frati A, Enrici MM, Marchetti P, Enrici RM.
Short-term radiotherapy followed by adjuvant chemotherapy in poor-prognosis patients with glioblastoma.
Tumori. 2010 Jan-Feb;96(1):60-4.
Source | Abstract | Full text | Similar articles



RADIATION-ENHANCING AGENTS



Kleinberg L, Grossman SA, Carson K, Lesser G, O'Neill A, Pearlman J,Phillips P, Herman T, Gerber M.
Survival of Patients With Newly Diagnosed Glioblastoma Multiforme Treated With RSR13 and Radiotherapy: Results of a Phase II New Approaches to Brain Tumor Therapy CNS Consortium Safety and Efficacy Study
J Clin Oncol. 2002 Jul 15;20(14):3149-55

Source | Abstract | Full text | Similar articles



SURGERY



Della Puppa A, Lombardi G, Rossetto M, Rustemi O, Berti F, Cecchin D, Gardiman MP, Rolma G, Persano L, Zagonel V, Scienza R.
Outcome of patients affected by newly diagnosed glioblastoma undergoing surgery assisted by 5-aminolevulinic acid guided resection followed by BCNU wafers implantation: a 3-year follow-up.
J Neurooncol. 2016 Oct 18. [Epub ahead of print]
Source | Abstract | Full text | Similar articles




Li XZ, Li YB, Cao Y, Li PL, Liang B, Sun JD, Feng ES.
Prognostic implications of resection extent for patients with glioblastoma multiforme: a meta-analysis.
J Neurosurg Sci. 2016 Jan 29. [Epub ahead of print]
Source | Abstract | Full text | Similar articles



EXTENT OF RESECTION AND SURVIVAL



Brown TJ, Glantz M.
Extent of Resection and Survival in Glioblastoma Multiforme-Reply.
JAMA Oncol. 2016 Nov 1;2(11):1509-1510. doi: 10.1001/jamaoncol.2016.3812. Epub 2016 Sep 29.
Source | Abstract | Full text | Similar articles




Brown TJ, Brennan MC, Li M, Church EW, Brandmeir NJ, Rakszawski KL, Patel AS, Rizk EB, Suki D, Sawaya R, Glantz M.
Association of the Extent of Resection With Survival in Glioblastoma: A Systematic Review and Meta-analysis.
JAMA Oncol. 2016 Nov 1;2(11):1460-1469. doi: 10.1001/jamaoncol.2016.1373. Epub 2016 Jun 16.
Source | Abstract | Full text | Similar articles




Grasso G.
Extent of Resection and Survival in Glioblastoma Multiforme.
JAMA Oncol. 2016 Nov 1;2(11):1508-1509. doi: 10.1001/jamaoncol.2016.3806. Epub 2016 Sep 29.
Source | Abstract | Full text | Similar articles




Jabbour W, Wion D.
Extent of Resection and Survival in Glioblastoma Multiforme.
JAMA Oncol. 2016 Nov 1;2(11):1509. doi: 10.1001/jamaoncol.2016.3809. Epub 2016 Sep 29.
Source | Abstract | Full text | Similar articles




Khan MB, Chakraborty S, Boockvar JA.
Gross Total Resection of Glioblastoma Improves Overall Survival and Progression-Free Survival Compared to Subtotal Resection or Biopsy Alone.
Neurosurgery. 2016 Dec;79(6):N12-N13.
Source | Abstract | Full text | Similar articles



VALPROIC ACID



Happold C, Gorlia T, Chinot O, Gilbert MR, Nabors LB, Wick W, Pugh SL, Hegi M, Cloughesy T, Roth P, Reardon DA, Perry JR, Mehta MP, Stupp R, Weller M.
Does Valproic Acid or Levetiracetam Improve Survival in Glioblastoma? A Pooled Analysis of Prospective Clinical Trials in Newly Diagnosed Glioblastoma.
J Clin Oncol. 2016 Mar 1;34(7):731-9. doi: 10.1200/JCO.2015.63.6563. Epub 2016 Jan 19.
Source | Abstract | Full text | Similar articles



VENTRICULAR ZONE



Mistry AM, Hale AT, Chambless LB, Weaver KD, Thompson RC, Ihrie RA.
Influence of glioblastoma contact with the lateral ventricle on survival: a meta-analysis.
J Neurooncol. 2016 Sep 19. [Epub ahead of print]
Source | Abstract | Full text | Similar articles



Recurrent tumors



OVERVIEWS



Tipping M, Eickhoff J, Ian Robins H.
Clinical outcomes in recurrent glioblastoma with bevacizumab therapy: An analysis of the literature.
J Clin Neurosci. 2017 Oct;44:101-106. doi: 10.1016/j.jocn.2017.06.070. Epub 2017 Jul 12.
Source | Abstract | Full text | Similar articles




van Linde ME, Brahm CG, de Witt Hamer PC, Reijneveld JC, Bruynzeel AME, Vandertop WP, van de Ven PM, Wagemakers M, van der Weide HL, Enting RH, Walenkamp AME, Verheul HMW.
Treatment outcome of patients with recurrent glioblastoma multiforme: a retrospective multicenter analysis.
J Neurooncol. 2017 Jul 20. doi: 10.1007/s11060-017-2564-z. [Epub ahead of print]
Source | Abstract | Full text | Similar articles



IMAGING



Brandes AA, Finocchiaro G, Zagonel V, Reni M, Fabi A, Caserta C, Tosoni A, Eoli M, Lombardi G, Clavarezza M, Paccapelo A, Bartolini S, Cirillo L, Agati R, Franceschi E.
Early tumour shrinkage as a survival predictor in patients with recurrent glioblastoma treated with bevacizumab in the AVAREG randomized phase II study.
Oncotarget. 2017 Feb 25. doi: 10.18632/oncotarget.15735. [Epub ahead of print]
Source | Abstract | Full text | Similar articles




Chiang GC, Galla N, Ferraro R, Kovanlikaya I.
The Added Prognostic Value of Metabolic Tumor Size on FDG-PET at First Suspected Recurrence of Glioblastoma Multiforme.
J Neuroimaging. 2016 Aug 12. doi: 10.1111/jon.12386. [Epub ahead of print]
Source | Abstract | Full text | Similar articles




Field KM, Phal PM, Fitt G, Goh C, Nowak AK, Rosenthal MA, Simes J, Barnes EH, Sawkins K, Cher LM, Hovey EJ, Wheeler H.
The role of early magnetic resonance imaging in predicting survival on bevacizumab for recurrent glioblastoma: Results from a prospective clinical trial (CABARET).
Cancer. 2017 Jul 5. doi: 10.1002/cncr.30838. [Epub ahead of print]
Source | Abstract | Full text | Similar articles




Hassanzadeh C, Rao YJ, Chundury A, Rowe J, Ponisio MR, Sharma A, Miller-Thomas M, Tsien CI, Ippolito JE.
Multiparametric MRI and [18F]Fluorodeoxyglucose Positron Emission Tomography Imaging Is a Potential Prognostic Imaging Biomarker in Recurrent Glioblastoma.
Front Oncol. 2017 Aug 18;7:178. doi: 10.3389/fonc.2017.00178. eCollection 2017.
Source | Abstract | Full text | Similar articles



MGMT METHYLATION STATUS



Brandes AA, Franceschi E, Paccapelo A, Tallini G, De Biase D, Ghimenton C, Danieli D, Zunarelli E, Lanza G, Silini EM, Sturiale C, Volpin L, Servadei F, Talacchi A, Fioravanti A, Pia Foschini M, Bartolini S, Pession A, Ermani M.
Role of MGMT Methylation Status at Time of Diagnosis and Recurrence for Patients with Glioblastoma: Clinical Implications.
Oncologist. 2017 Mar 8. pii: theoncologist.2016-0254. doi: 10.1634/theoncologist.2016-0254. [Epub ahead of print]

Source | Abstract | Full text | Similar articles



PATTERN OF RECURRENCE



Chan DT, Hsieh SY, Kam MK, Cheung TC, Ng SC, Poon WS.
Pattern of recurrence and factors associated with cerebrospinal fluid dissemination of glioblastoma in Chinese patients.
Surg Neurol Int. 2016 Oct 20;7:92.
Source | Abstract | Full text | Similar articles




Tini P, Nardone V, Pastina P, Battaglia G, Miracco C, Carbone SF, Sebaste L, Rubino G, Cerase A, Pirtoli L.
Epidermal Growth Factor Receptor Expression predicts Time and Patterns of Recurrence in Glioblastoma Patients Following Radiotherapy and Temozolomide.
World Neurosurg. 2017 Oct 20. pii: S1878-8750(17)31779-5. doi: 10.1016/j.wneu.2017.10.052. [Epub ahead of print]
Source | Abstract | Full text | Similar articles



The aim is to investigate the potential role of EGFR protein expression in predicting the modality of treatment failure in Glioblastoma (GB).
... it is known that EGFR may be activated by irradiation signaling. Following radiation, DSB DNA repair by Non-Homologous End Joining (NHEJ) are mainly induced by activated EGFR, [25], thus conferring radiation resistance to GB. EGFR signaling may also influence GB cell migration, as EGFR inhibition induces a decreased cell motility [42], which is in line with our observation of a higher rate of marginal and distant recurrences in GB highly expressing EGFR.
Our experience, which we consider as a pilot study, may envisage novel approaches on RT planning policy in GB. The current trend towards narrow target volumes in postoperative RT-TMZ protocols [5] should be critically considered in H-EGFR expressing GBs, in our opinion. In high EGFR-expressing GBs, in fact, improving disease control might need not only an enhancement of local cell killing, but also effective strategies to cope with the diffusion of tumor beyond RT volumes. Conversely, studies dealing with RT dose-escalation, hypofractionation, or high-LET particle therapy on very selective treatment volumes, and with steep gradients, might be preferentially suitable to low EGFR-expressing GBs.



POSTPROGRESSION SURVIVAL



Majewska P, Ioannidis S, Raza MH, Tanna N, Bulbeck H, Williams M.
Postprogression survival in patients with glioblastoma treated with concurrent chemoradiotherapy: a routine care cohort study.
CNS Oncol. 2017 Oct 9. doi: 10.2217/cns-2017-0001. [Epub ahead of print]
Source | Abstract | Full text | Similar articles



RELAPSE PREDICTION



Khalifa J, Tensaouti F, Lotterie JA, Catalaa I, Chaltiel L, Benouaich-Amiel A, Gomez-Roca C, Noël G, Truc G, Péran P, Berry I, Sunyach MP, Charissoux M, Johnson C, Cohen-Jonathan Moyal E, Laprie A.
Do perfusion and diffusion MRI predict glioblastoma relapse sites following chemoradiation?
J Neurooncol. 2016 Oct;130(1):181-192. Epub 2016 Aug 8.
Source | Abstract | Full text | Similar articles




Villanueva-Meyer JE, Han SJ, Cha S, Butowski NA.
Early tumor growth between initial resection and radiotherapy of glioblastoma: incidence and impact on clinical outcomes.
J Neurooncol. 2017 May 31. doi: 10.1007/s11060-017-2511-z. [Epub ahead of print]
Source | Abstract | Full text | Similar articles



RADIOTHERAPY



Zwirner K, Paulsen F, Schittenhelm J, Borchers C, Skardelly M, Zips D, Eckert F.
Prognostic parameters and outcome after re-irradiation for progressive glioblastoma.
Acta Neurol Scand. 2016 Dec 26. doi: 10.1111/ane.12719. [Epub ahead of print]
Source | Abstract | Full text | Similar articles



ELDERLY PATIENTS



Lombardi G, Pace A, Pasqualetti F, Rizzato S, Faedi M, Anghileri E, Nicolotto E, Bazzoli E, Bellu L, Villani V, Fabi A, Ferrazza P, Gurrieri L, Dall'Agata M, Eoli M, Della Puppa A, Pambuku A, D'Avella D, Berti F, Rudà R, Zagonel V.
Predictors of survival and effect of short (40 Gy) or standard-course (60 Gy) irradiation plus concomitant temozolomide in elderly patients with glioblastoma: a multicenter retrospective study of AINO (Italian Association of Neuro-Oncology).
J Neurooncol. 2015 Nov;125(2):359-67. doi: 10.1007/s11060-015-1923-x. Epub 2015 Sep 30.
Source | Abstract | Full text | Similar articles



SURGERY


RESECTION OF RADIATION NECROSIS



Grossman R, Shimony N, Hadelsberg U, Soffer D, Sitt R, Strauss N, Corn BW, Ram Z.
Impact of Resecting Radiation Necrosis and Pseudoprogression on Survival of Patients with Glioblastoma.
World Neurosurg. 2016 May;89:37-41. doi: 10.1016/j.wneu.2016.01.020. Epub 2016 Jan 22.
Source | Abstract | Full text | Similar articles



RESECTION OF CONTRAST-ENHANCING TUMOR VOLUME



Suchorska B, Weller M, Tabatabai G, Senft C, Hau P, Sabel MC, Herrlinger U, Ketter R, Schlegel U, Marosi C, Reifenberger G, Wick W, Tonn JC, Wirsching HG.
Complete resection of contrast-enhancing tumor volume is associated with improved survival in recurrent glioblastoma-results from the DIRECTOR trial.
Neuro Oncol. 2016 Apr;18(4):549-56. doi: 10.1093/neuonc/nov326. Epub 2016 Jan 27.
Source | Meeting abstract | Abstract | Full text | Similar articles



REPEAT SURGERY



Azoulay M, Santos F, Shenouda G, Petrecca K, Oweida A, Guiot MC, Owen S, Panet-Raymond V, Souhami L, Abdulkarim BS.
Benefit of re-operation and salvage therapies for recurrent glioblastoma multiforme: results from a single institution.
J Neurooncol. 2017 Apr 3. doi: 10.1007/s11060-017-2383-2. [Epub ahead of print]
Source | Abstract | Full text | Similar articles




Perrini P, Gambacciani C, Weiss A, Pasqualetti F, Delishaj D, Paiar F, Morganti R, Vannozzi R, Lutzemberger L.
Survival outcomes following repeat surgery for recurrent glioblastoma: a single-center retrospective analysis.
J Neurooncol. 2016 Nov 14. [Epub ahead of print]
Source | Abstract | Full text | Similar articles




Pessina F, Navarria P, Cozzi L, Tomatis S, Riva M, Ascolese AM, Santoro A, Simonelli M, Bello L, Scorsetti M.
Role of surgical resection in recurrent glioblastoma: prognostic factors and outcome evaluation in an observational study.
J Neurooncol. 2016 Nov 8. [Epub ahead of print]
Source | Abstract | Full text | Similar articles





Gliosarcoma variant





Frandsen J, Orton A, Jensen R, Colman H, Cohen AL, Tward J, Shrieve DC, Suneja G.
Patterns of care and outcomes in gliosarcoma: an analysis of the National Cancer Database.
J Neurosurg. 2017 Jun 16:1-6. doi: 10.3171/2016.12.JNS162291. [Epub ahead of print]
Source | Abstract | Full text | Similar articles




Zhang G, Huang S, Zhang J, Wu Z, Lin S, Wang Y.
Clinical outcome of gliosarcoma compared with glioblastoma multiforme: a clinical study in Chinese patients.
J Neurooncol. 2016 Apr;127(2):355-62. doi: 10.1007/s11060-015-2046-0. Epub 2016 Jan 2.
Source | Abstract | Full text | Similar articles